Abstract
The human lung mast cell is known to be a critical effector cell in the mediation of asthma. Activation of the mast cell by allergens and other stimuli leads to the release and generation of a wide variety of autacoids that cause bronchoconstriction, promote inflammation, and may influence airway remodeling. Therefore, the stabilization of mast cells has obvious value in the prevention of asthma. Among the drugs used to treat asthma, only β-agonists are effective stabilizers of mast cells. Both short- and long-acting β-agonists are effective against mast cells, but there are differences between agonists regarding the extent of inhibitory activity attained. Consequently, the type of β-agonist prescribed influences the degree of mast cell stabilization possible. Despite the potential value of attenuating mast cell activity with β-agonists, this benefit may diminish with time because of the development of tolerance. Both short- and long-acting β-agonists can induce tolerance to mast cell stabilization, and generally, higher efficacy agonists tend to induce greater levels of tolerance; however, weaker agonists induce greater levels of tolerance than might be expected. Tolerance to the mast-cell-stabilizing effects of β-agonists may be an issue clinically, because this occurs more readily than tolerance to smooth muscle relaxation. This could lead to a situation in which β-agonists fail to prevent the release of mediators from mast cells but can still effectively relax airway smooth muscle. The continued ability to bronchodilate could mask the unfavorable consequences of unchecked mediator release from mast cells.
Similar content being viewed by others
References
Holgate, S. T., Hardy, C., Robinson, C., Agius, R. M., and Howarth, P. H. (1986), The mast cell as a primary effector cell in the pathogenesis of asthma. J. Allergy Clin. Immunol. 79, 274–282.
Bingham, C. O. and Austen, K. F. (2000), Mast-cell responses in the development of asthma. J. Allergy Clin. Immunol. 105, S527-S534.
Williams, C. M. M. and Galli, S. J. (2000), The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. Immunol. 105, 847–859.
Holgate, S. T., Peters-Golden, M., Panettieri, R. A., and Henderson, W. R. (2003), Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111, S18-S36.
Reed, C. E. and Kita, H. (2004), The role of protease activation of inflammation in allergic respiratory diseases. J. Allergy Clin. Immunol. 114, 997–1008.
Elias, J. A., Zhou, Z., Chupp, G., and Homer, R. J. (1999), Airway remodeling in asthma. J. Clin. Invest. 104, 1001–1006.
Sommerhoff, C. P. (2001), Mast cell tryptases and airway remodeling. Am. J. Respir. Crit. Care Med. 164, S52-S58.
Brightling, C. J., Bradding, P., Symon, F. A., Holgate, S. T., Wardlaw, A. J., and Pavord, I. D. (2002), Mast-cell infiltration of airway smooth muscle in asthma. N. Eng. J. Med. 346, 1699–1705.
Robinson, D. S. (2004), The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J. Allergy Clin. Immunol. 114, 58–65.
Peachell, P. (2005), Targeting the mast cell in asthma. Curr. Opin. Pharmacol. 5, 251–256.
Waldeck, B. (2002), β-adrenoceptor agonists and asthma—100 years of development. Eur. J. Pharmacol. 445, 1–12.
O'Connor, B. J., Fuller, R. W., and Barnes, P. J. (1994), Non-bronchodilator effects of inhaled β2-agonists. Greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 150, 381–387.
Lee, D. K. C., Gray, R. D., and Lipworth, B. J. (2003), Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clin. Exp. Allergy 33, 287–294.
Cushley, M. J. and Holgate, S. T. (1985), Adenosine-induced bronchoconstriction in asthma: role of mast cell mediator release. J. Allergy Clin. Immunol. 78, 272–278.
Salpeter, S. R., Ormistor, T. M., and Salpeter, E. E. (2004), Meta-analysis: respiratory tolerance to regular β2-agonist use in patients with asthma. Ann. Intern. Med. 140, 802–813.
Cockcroft, D. W., McParland, C. P., Britto, S. A., Swystun, V. A., and Rutherford, B. C. (1993), Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342, 833–837.
O'Connor, B. J., Aikman, S. L., and Barnes P. J. (1992), Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma. N. Engl. J. Med. 327, 1204–1208.
Jokic, R., Swystun, V. A., Davis, B. E., and Cockcroft, D. W. (2001), Regular inhaled salbutamol. Effect on airway responsiveness to methacholine and adenosine 5′-monophosphate and tolerance to bronchoprotection. Chest 119, 370–375.
Swystun, V. A., Gordon, J. R., Davis, B., Zhang, X., and Cockcroft, D. W. (2000), Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J. Allergy Clin. Immunol. 106, 57–64.
Schild, H. (1937), Histamine release in anaphylactic shock of isolated lungs of guinea pigs. Quart. J. Exp. Physiol. 26, 165–179.
Orange, R. P., Austen, W. G., and Austen, K. F. (1971), Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3′5′-adenosine monophosphate. J. Exp. Med. 134, 136–148.
Assem, E. S. K. and Schild, H. O. (1969), Beta-adrenergic receptors concerned with the anaphylactic mechanism. Int. Archs Allergy Appl. Immunol. 45, 62–69.
Butchers, P. R., Skidmore, I. F., Vardey, C. J., and Wheeldon, A. (1980), Characterisation of the receptor mediating the anti-anaphylactic effects of β-adrenoceptor agonists in human lung tissue in vitro. Br. J. Pharmacol. 17, 663–667.
Nials, A. T., Ball, D. I., Butchers, P. R., et al. (1994), Formoterol on airway smooth muscle and human lung mast cells—a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 251, 127–135.
Lau, H. Y. A., Wong, P. L. E., Lai, C. K. W., and Ho, J. K. S. (1994), Effects of long-acting β2-adrenoceptor agonists on mast cells of rat, guinea pig, and human. Int. Arch. Allergy Immunol. 105, 177–180.
Church, M. K. and Hiroi, J. (1987), Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br. J. Pharmacol. 90, 421–429.
Chang, L. K., Suvarna, K., Chess-Williams, R., and Peachell, P. T. (2003), Desensitization of β2-adrenoceptor-mediated responses by short-acting β2-adrenoceptor agonists in human lung mast cells. Br. J. Pharmacol. 138, 512–520.
Scola, A-M., Chong, L. K., Suvarna, S. K., Chess-Williams, R., and Peachell, P. T. (2004), Desensitisation of mast cell β2-adrenoceptor-mediated responses by salmeterol and formeterol. Br. J. Pharmacol. 141, 163–171.
Scola, A-M., Chong, L. K., Chess-Williams, R., and Peachell, P. T. (2004), Influence of agonist intrinsic activity on the desensitisation of β2-adrenoceptor-mediated responses in mast cells. Br. J. Pharmacol. 143, 71–80.
Undem, B. J., Peachell, P. T., and Lichtenstein, L. M. (1988), Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. J. Pharmacol. Exp. Ther. 247, 209–217.
Butchers, P. R., Vardey, C. J., and Johnson, M. (1991), Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 104, 672–676.
Chong, L. K., Cooper, E., Vardey, C. J., and Peachell, P. T. (1998), Salmeterol inhibition of mediator release from human lung mast cells by β-adrenoceptor-dependent and independent mechanisms. Br. J. Pharmacol. 123, 1009–1015.
Howarth, P. H., Durham, S. H., Lee, T. M., Kay, A. B., Church, M. K., and Holgate, S. T. (1985), Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am. Rev. Respir. Dis. 132, 986–992.
Chong, L. K., Chess-Williams, R., and Peachell, P. T. (2002), Pharmacological characterisation of the β-adrenoceptor expressed by human lung mast cells. Eur. J. Pharmacol. 437, 1–7.
Proud, D., Reynolds, C. J., Lichtenstein, L. M., Kagey-Sobotka, A., and Togias A. (1998), Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin. Exp. Allergy 28, 868–875.
Taylor, D. A., Jensen, M. W., Aikman, S. L., Harris, J. G., Barnes, P. J., and O'Connor, B. J. (1997), Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Crit. Care Med. 136, 1731–1737.
Russo, C., Zeng, D., Prosperini, G., Spicuzza, L., Guarino, F., and Polosa, R. (2005), Effect of salbutamol on nasal symptoms and mast cell degranulation induced by adenosine 5′ monophosphate nasal challenge. Clin. Exp. Allergy 35, 1192–1196.
Nightingale, J. A., Rogers, D. F., and Barnes, P. J. (1999), Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am. J. Respir. Crit. Care Med. 159, 1786–1790.
Ketchell, R. I., Jensen, M. W., Spina, D., and O'Connor, B. J. (2002), Dose-related effects of formoterol on airway responsiveness to adenosine 5′ monophosphate and histamine. Eur. Respir. J. 19, 611–616.
Drury, D. E. J., Chong, L. K., Ghahramani, P., and Peachell, P. T. (1998), Influence of receptor reserve on β-adrenoceptor-mediated responses in human lung mast cells. Br. J. Pharmacol. 124, 711–718.
MacEwan, D. J., Kim, G. D., and Milligan, G. (1995), Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human β2-adrenoceptor. Mol. Pharmacol. 48, 316–325.
Peachell, P. T., MacGlashan, D. W., Lichtenstein, L. M., and Schleimer, R. P. (1988), Regulation of human basophil and lung mast cell function by cAMP. J. Immunol. 140, 571–579.
Falcone, F. H., Haas, H., and Gibbs, B. F. (2000), The human basophil: a new appreciation of its role in immune responses. Blood 96, 4028–4038.
Botana, L. M. and MacGlashan, D. W. (1994), Differential effects of cAMP-elevating drugs on stimulus-induced calcium changes in human basophils. J. Leuk. Biol. 55, 798–804.
Su, Y-F., Harden, T. K., and Perkins, J. P. (1980), Catecholamine-specific desensitization of adenylate cyclase; evidence for a multi-step process. J. Biol. Chem. 255, 7410–7419.
Ferguson, S. S. G. (2001), Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1–24.
Kohout, T. A. and Lefkowitz, R. J. (2003), Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9–18.
Benovic, J. L., Staniszewski, C., Mayor, F., Caron, M. G., and Lefkowitz, R. J. (1988), β-adrenergic kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J. Biol. Chem. 263, 3893–3897.
January, B., Seibold, A., Whaley, B., et al. (1997), β2-Adrenergic receptor desensitization, internaliza-tion, and phosphorylation in response to full and partial agonists. J. Biol. Chem., 272, 23,871–23,879.
Giembycz, M. A. (1996). Phosphodiesterase 4 and tolerance to b2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci. 17, 331–336.
Pinney, P. A., Donnelly, L. E., Belvisi, M. G., et al. (2001). Chronic systemic administration of salmeterol to rats promotes pulmonary β2-adrenoceptor desensitization and down-regulation of Gsa. Br. J. Pharmacol. 132, 1261–1270.
Finney, P. A., Belvisi, M. G., Donnelly, L. E., et al. (2000), Albuterol-induced down-regulation of Gsa accounts for pulmonary β2-adrenoceptor desensitization in vivo. J. Clin. Invest. 106, 125–135.
Chong, L. K., Morice, A. H., Yeo, W. W., Schleimer, R. P., and Peachell, P. T. (1995). Functional desensitization of β-agonist responses in human lung mast cells. Am. J. Respir. Cell Mol. Biol. 13, 540–546.
Chong, L. K., Drury, D. E. J., Dummer, J. F., Ghahramani, P., Schleimer, R. P., and Peachell, P. T. (1997), Protection by dexamethasone of the functional desensitization to b2-adrenoceptor-mediated responses in human lung mast cells. Br. J. Pharmacol. 121, 717–722.
Chong, L. K. and Peachell, P. T. (1999), β-adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. Eur. J. Pharmacol. 372, 115–122.
Van der Hollden, P. J. C. M., Van Amsterdam, J. G. C., and Zaagsma, J. (1984), Desensitization of smooth muscle and mast cell β-adrenoceptors in the airways of the guinea pig. Eur. J. Resp. Dis. (supplement 135) 65, 128–134.
Bremner, P., Siebers, R., Crane, J., Beasley, R., and Burgess, C. Partial vs full beta-receptor agonism: A clinical study of inhaled albuterol and fenoterol. Chest 109, 957–962.
Hanania, N. A., Sharafkhaneh, A., Barber, R., and Dickey, B. F. (2002), β-agonist intrinsic efficacy. Measurement and clinical significance. Am. J. Respir. Crit. Care Med. 165, 1353–1358.
Clark, R. B., Knoll, B. J., and Barber, R. (1999). Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol. Sci. 20, 279–286.
Pittman, R. N., Reynolds, E. E., and Molinoff, P. B. (1984), Relationship between intrinsic activities of agonists in normal and desensitized tissue and agonist-induced loss of beta-adrenergic receptors. J. Pharmacol. Exp. Ther. 230, 614–618.
Maudsley, S., Martin, B., and Luttrell, L. M. (2005), The origins of diversity and specificity in G-protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. 314, 485–494.
Yates, D. H., Wordsell, M., and Barnes, P. J. (1997). Effect of regular salmoterol treatment on albuterol-induced bronchoprotection in mild asthma. Am. J. Respir. Care Med. 156, 988–991.
Van Der Woude, H. J., Winter, T. H., and Aalbers, R. (2001), Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long-acting β2-agonists. Thorax 56, 529–535.
Grove, A. and Lipworth, R. J. (1995). Bronchedilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346, 201–206.
Hauck, R. W., Bohm, M., Gegenbach, S., Sunder-Plassmann, L., Fruhmann, G., and Erdmann, E. (1990), β2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Chest 98, 376–381.
Bai, T. B., Mak, J. C. W., and Barnes, P. J. (1992), A comparison of β-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 6, 647–651.
Hasegawa, M. and Townley, R. G. (1983), Difference between lung and spleen susceptibility of beta-adrenergic receptors to desensitization by terbutaline. J. Allergy Clin. Immunol. 71, 230–238.
Herepath, M. L., and Broadley, K. J. (1992), Resistance of β2-adrenoceptor-mediated responses of lung strips to desensitization by long-term agonist exposure-comparison with atrial β2-adrenoceptor-mediated responses. Eur. J. Pharmacol. 215, 209–219.
Kirstein, S. I. and Insel, P. A. (2004). Autonomic nervous system Pharmacogenomics: a progress report. Pharmacol. Rev. 56, 31–52.
Green, S. A., Turki, J., Hall, I. P., and Liggett, S. B. (1995), Implications of genetic variability of human β2-adrenergic receptor structure. Pulmon. Pharmacol. 8, 1–10.
Green, S. A., Cole, G., Jacinto, M., Innis, M., and Liggett, S. B. (1993), A polymorphism of the human β2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268, 23,116–23,121.
McGraw, D. W., Forbes, S. L., Kramer, L. A., and Liggett, S. B. (1998), Polymorphisms of the 5′ leader cistron of the human β2-adrenergic receptor regulate receptor expression. J. Clin. Invest. 102, 1927–1932.
Büscher, R., Herrmann, V., and Insel, P. A. (1999), Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol. Sci. 20, 94–99.
Taylor, D. R. and Kennedy, M. A. (2002), Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics 3, 173–184.
Kay, L. J., Cheng, L. K., Rostami-Hodjegan, A., and Peacheli, P. T. (2003), Influence of the th164lle polymorphism in the β2-adrenoceptor on the effects of β-adrenoceptor agonists on human lung mast cells. Int. Immunopharmacol. 3, 91–95.
Green, S. A., Cole, G., Forbes, S. L., Kramer, L. A., and Liggett, S. B. (2001), The Ile164 β2-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to Gs, Eur. J. Pharmacol. 421, 141–147.
Reihsaus, E., Innis, M., MacIntyre, N., and Liggett, S. B. (1993), Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8, 334–339.
Aynacioglu, A. S., Cascorbi, I., Güngör, K., et al., (1999), Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the β2-adrenergic receptor among Turks. Br. J. Clin. Pharmacol. 48, 761–764.
Green, S. A., Turki, J., Innis, M., and Liggett, S. B. (1994), Amino-terminal polymorphisms of the human β2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33, 9414–9419.
Green, S. A., Turki, J., Bejarano, P., Hall, I. P., and Liggett, S. B. (1995), Influence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25–33.
Chong, L. K., Chowdry, J., Ghahramani, P., and Peachell, P. T. (2000), Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells. Pharmacogenetics 10, 153–162.
Drysdale, C. M., McGraw, D. W., Stack, C. B., et al. (2000), Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97, 10,483–10,488.
Lipworth, B., Koppelman, G. H., Wheatley, A. P., et al. (2002), β2-adrenoceptor polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 57, 61–66.
Taylor, D. R., Epton, M. J., Kennedy, M. A., et al. (2005), Bronchodilator reponse in relation to β2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. 172, 700–703.
Oostendorp, J., Postma, D. S., Volders, H., et al. (2005), Differential desensitization of homozygous haplotypes of the β2-adrenergic receptor in lymphocytes. Am. J. Respir. Crit. Care Med. 172, 322–328.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peachell, P. Regulation of mast cells by β-agonists. Clinic Rev Allerg Immunol 31, 131–141 (2006). https://doi.org/10.1385/CRIAI:31:2:131
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:31:2:131